Anti-Biopharmaceutical Immunization: prediction
and analysis of clinical relevance to minimize the RISK
IBD prospective cohort recruitment period prolongation is voted by the Steering Committee
WP3 data integration innovative tool goes live internally for test runs
ABIRISK is invited to speak at the TransMART Foundation Annual Meeting
FIRST ABIRISK DRUG IMMUNOGENICITY CONFERENCE Innsbruck Medical University, Innsbruck, Austria - 1st April 2016
Download the flyer |
ABIRISK holds a Satellite Symposium on «Immunogenicity of Biopharmaceuticals» at the European Congress of Immunology in Vienna on September 6th
Recruitment of patients in the Inflammatory Bowel Disease cohort exceeds projections!
ABIRISK project is granted a 9 months extension by IMI to maximize the productivity and impact of the project. New end date: 30th November 2017
ABIRISK welcome comments from the community on its white paper on Standardization of Terms and Definitions related to Immunogenicity of biopharmaceuticals
First Juvenile Idiopathic Arthritis (JIA) patients enrolled in Greece
ABIRISK Autumn Face-to-Face Steering Committee meeting in Copenhagen, hosted by our partner Novo Nordisk
ABIRISK presentation at ProImmune Mastering Immunogenicity Conference, Boston, USA
ABIRISK Project is a Hot Topic Session at the 2014 National Biotechnology Conference May 19-21, 2014, San Diego, California
For prospective clinical trials, ABIRISK prepared 133511 tubes. Thank you to the GSK team that did the job
ABIRISK General Assembly in Brussels rassembled over 100 participants, with a whole day dedicated
View the gallery |
Gabriele Reichmann from the Paul Erlich Institute, Germany joins ABIRISK Scientific Advisory Board
First Multiple sclerosis patient enrolled in Austria
PREDICTION OF IMMUNOGENICITY: THE FUTURE IN VIEW CORAL GABLES SYMPOSIUM (Miami, April 24-26, 2013)
EPMT & SC Meetings (September 2012)
WP1 Assay Workshop (December 4th, 2012) |
March 2012 - Kick-off meeting fact sheet |
March 2012 - Kick-off meeting team photo |